This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhalla, I. A.
Right arrow Articles by Juurlink, D. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhalla, I. A.
Right arrow Articles by Juurlink, D. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2006, p. 3216-3219, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00592-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium difficile-Associated Disease?

Irfan A. Dhalla,1,8* Muhammad M. Mamdani,2,7,8,{dagger} Andrew E. Simor,1,3,4,5 Alex Kopp,8 Paula A. Rochon,1,6,7,8 and David N. Juurlink1,4,7,8

Department of Medicine,1 Department of Pharmacy,2 Department of Laboratory Medicine and Pathobiology,3 Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada,7 Department of Medicine,4 Department of Microbiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada,5 Kunin-Lunenfeld Applied Research Unit, Baycrest Research Centre for Aging and the Brain, Toronto, Ontario, Canada,6 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada8

Received 14 May 2006/ Returned for modification 11 June 2006/ Accepted 2 July 2006

Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.

* Corresponding author. Mailing address: 35 Fernwood Park Ave., Toronto, Ontario M4E 3E9, Canada. Phone: (416) 699-5973. Fax: (416) 480-6048. E-mail: irfan.dhalla{at}utoronto.ca.

{dagger} Present address: Pfizer, Inc., New York, N.Y.

Antimicrobial Agents and Chemotherapy, September 2006, p. 3216-3219, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00592-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Blondeau, J. M. (2009). What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?. J Antimicrob Chemother 63: 238-242 [Abstract] [Full Text]  
  • Gallagher, J. C, Du, J. K, Rose, C. (2009). Severe Pseudomembranous Colitis After Moxifloxacin Use: A Case Series. The Annals of Pharmacotherapy 43: 123-128 [Abstract] [Full Text]  
  • Wilcox, M. H., Mooney, L., Bendall, R., Settle, C. D., Fawley, W. N. (2008). A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 62: 388-396 [Abstract] [Full Text]  
  • Mehlhorn, A. J, Brown, D. A (2007). Safety Concerns with Fluoroquinolones. The Annals of Pharmacotherapy 41: 1859-1866 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»